Last reviewed · How we verify
Klaricid based triple therapy — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Klaricid based triple therapy (Klaricid based triple therapy) — National Taiwan University Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Klaricid based triple therapy TARGET | Klaricid based triple therapy | National Taiwan University Hospital | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Klaricid based triple therapy CI watch — RSS
- Klaricid based triple therapy CI watch — Atom
- Klaricid based triple therapy CI watch — JSON
- Klaricid based triple therapy alone — RSS
Cite this brief
Drug Landscape (2026). Klaricid based triple therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/klaricid-based-triple-therapy. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing